Is Pegasys Approved for Hepatitis C?
Yes, Pegasys (peginterferon alfa-2a) is FDA-approved for treating chronic hepatitis C virus (HCV) infection in adults and children aged 5 and older. It works by boosting the immune response to fight the virus and is typically combined with ribavirin for genotypes 1-6.[1][2]
How Is Pegasys Used for Hepatitis C?
Pegasys is given as a weekly subcutaneous injection, usually for 24-48 weeks depending on genotype, viral load, and patient response. It's often paired with ribavirin to improve sustained virologic response rates, which can reach 40-50% for some genotypes in older studies.[1][3] Treatment success is measured by undetectable HCV RNA 24 weeks post-therapy.
Why Is Pegasys Rarely Used Today for Hep C?
Direct-acting antivirals (DAAs) like sofosbuvir (Sovaldi) or glecaprevir/pibrentasvir (Mavyret) have largely replaced Pegasys since 2014. DAAs cure over 95% of cases in 8-12 weeks with fewer side effects and no interferon needed.[4] Guidelines from AASLD/IDSA now recommend DAAs as first-line, reserving interferon-based regimens like Pegasys for rare cases, such as DAA failures or specific coinfections.[3]
What Are Common Side Effects with Pegasys?
Patients report flu-like symptoms (fever, fatigue, muscle aches), depression, anemia, and thyroid issues. Up to 10-20% drop out due to intolerance. Black-box warnings cover neuropsychiatric effects, autoimmune disorders, and growth issues in kids.[1][2] Monitoring includes blood counts and mental health checks.
Can Pegasys Treat Hep C in Special Cases?
It's still an option for interferon-eligible patients with decompensated liver disease, HIV/HCV coinfection, or post-transplant settings where DAAs aren't suitable. Off-label use occurs in some resource-limited areas due to DAA costs.[3][5] Consult a hepatologist for personalized regimens.
When Does Pegasys Patent Expire?
Key U.S. patents on Pegasys expired in 2019-2022, allowing generics like pegylated interferon alfa-2a. No active exclusivities block competition today.[6]
[1]: FDA Label - Pegasys (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103964s5253lbl.pdf)
[2]: Drugs.com - Pegasys (https://www.drugs.com/pegasys.html)
[3]: AASLD/IDSA HCV Guidance (https://www.hcvguidelines.org/)
[4]: NEJM - DAA Revolution in HCV (https://www.nejm.org/doi/full/10.1056/NEJMra1703880)
[5]: WHO Hep C Guidelines (https://www.who.int/publications/i/item/9789240032670)
[6]: DrugPatentWatch - Pegasys (https://www.drugpatentwatch.com/p/tradename/PEGASYS)